A Study to Investigate the Safety, Tolerability, Pharmacokinetics and Pharmacodynamics of Single and Repeat Doses of RV6153

NCT02517359 · clinicaltrials.gov ↗

PHASE1

Phase

TERMINATED

Status

55

Enrollment

INDUSTRY

Sponsor class

Stopped Preset pharmacokinetic stopping criteria met at lower doses than expected.

Conditions

Asthma
Healthy Volunteers

Interventions

DRUG: RV6153 single dose
DRUG: RV6153 matching placebo single dose
DRUG: RV6153 14 day repeat dose
DRUG: RV6153 matching placebo 14 day repeat dose
DRUG: RV6153 28 day repeat dose
DRUG: RV6153 matching placebo 28 day repeat dose

Sponsor

Respivert Ltd